MX2020006071A - Nuevas formas solidas de cannabidiol y sus usos. - Google Patents
Nuevas formas solidas de cannabidiol y sus usos.Info
- Publication number
- MX2020006071A MX2020006071A MX2020006071A MX2020006071A MX2020006071A MX 2020006071 A MX2020006071 A MX 2020006071A MX 2020006071 A MX2020006071 A MX 2020006071A MX 2020006071 A MX2020006071 A MX 2020006071A MX 2020006071 A MX2020006071 A MX 2020006071A
- Authority
- MX
- Mexico
- Prior art keywords
- cannabidiol
- solid forms
- new solid
- cocrystals
- proline
- Prior art date
Links
- QHMBSVQNZZTUGM-UHFFFAOYSA-N Trans-Cannabidiol Natural products OC1=CC(CCCCC)=CC(O)=C1C1C(C(C)=C)CCC(C)=C1 QHMBSVQNZZTUGM-UHFFFAOYSA-N 0.000 title abstract 3
- QHMBSVQNZZTUGM-ZWKOTPCHSA-N cannabidiol Chemical compound OC1=CC(CCCCC)=CC(O)=C1[C@H]1[C@H](C(C)=C)CCC(C)=C1 QHMBSVQNZZTUGM-ZWKOTPCHSA-N 0.000 title abstract 3
- 229950011318 cannabidiol Drugs 0.000 title abstract 3
- ZTGXAWYVTLUPDT-UHFFFAOYSA-N cannabidiol Natural products OC1=CC(CCCCC)=CC(O)=C1C1C(C(C)=C)CC=C(C)C1 ZTGXAWYVTLUPDT-UHFFFAOYSA-N 0.000 title abstract 3
- PCXRACLQFPRCBB-ZWKOTPCHSA-N dihydrocannabidiol Natural products OC1=CC(CCCCC)=CC(O)=C1[C@H]1[C@H](C(C)C)CCC(C)=C1 PCXRACLQFPRCBB-ZWKOTPCHSA-N 0.000 title abstract 3
- 239000007787 solid Substances 0.000 title 1
- FINHMKGKINIASC-UHFFFAOYSA-N Tetramethylpyrazine Chemical compound CC1=NC(C)=C(C)N=C1C FINHMKGKINIASC-UHFFFAOYSA-N 0.000 abstract 2
- 125000004433 nitrogen atom Chemical group N* 0.000 abstract 2
- MWVTWFVJZLCBMC-UHFFFAOYSA-N 4,4'-bipyridine Chemical group C1=NC=CC(C=2C=CN=CC=2)=C1 MWVTWFVJZLCBMC-UHFFFAOYSA-N 0.000 abstract 1
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 abstract 1
- ONIBWKKTOPOVIA-SCSAIBSYSA-N D-Proline Chemical compound OC(=O)[C@H]1CCCN1 ONIBWKKTOPOVIA-SCSAIBSYSA-N 0.000 abstract 1
- 229930182820 D-proline Natural products 0.000 abstract 1
- ONIBWKKTOPOVIA-BYPYZUCNSA-N L-Proline Chemical compound OC(=O)[C@@H]1CCCN1 ONIBWKKTOPOVIA-BYPYZUCNSA-N 0.000 abstract 1
- 229930182821 L-proline Natural products 0.000 abstract 1
- 229910052799 carbon Inorganic materials 0.000 abstract 1
- 229960002429 proline Drugs 0.000 abstract 1
- 229920006395 saturated elastomer Polymers 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C39/00—Compounds having at least one hydroxy or O-metal group bound to a carbon atom of a six-membered aromatic ring
- C07C39/23—Compounds having at least one hydroxy or O-metal group bound to a carbon atom of a six-membered aromatic ring polycyclic, containing six-membered aromatic rings and other rings, with unsaturation outside the aromatic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/045—Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates
- A61K31/05—Phenols
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
- A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
- A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
- A61K47/183—Amino acids, e.g. glycine, EDTA or aspartame
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
- A61K47/545—Heterocyclic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D207/04—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
- C07D207/10—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D207/16—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D241/00—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings
- C07D241/02—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings
- C07D241/10—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members
- C07D241/12—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B2200/00—Indexing scheme relating to specific properties of organic compounds
- C07B2200/13—Crystalline forms, e.g. polymorphs
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C2601/00—Systems containing only non-condensed rings
- C07C2601/12—Systems containing only non-condensed rings with a six-membered ring
- C07C2601/16—Systems containing only non-condensed rings with a six-membered ring the ring being unsaturated
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Pyrrole Compounds (AREA)
- Pyridine Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201762597307P | 2017-12-11 | 2017-12-11 | |
| PCT/US2018/064773 WO2019118360A1 (en) | 2017-12-11 | 2018-12-10 | New solid forms of cannabidiol and uses thereof |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MX2020006071A true MX2020006071A (es) | 2020-10-28 |
Family
ID=66735157
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2020006071A MX2020006071A (es) | 2017-12-11 | 2018-12-10 | Nuevas formas solidas de cannabidiol y sus usos. |
Country Status (11)
| Country | Link |
|---|---|
| US (4) | US20190177258A1 (ja) |
| EP (1) | EP3723752B1 (ja) |
| JP (1) | JP7429013B2 (ja) |
| KR (1) | KR20200097285A (ja) |
| CN (1) | CN111447929B (ja) |
| AU (1) | AU2018383598B2 (ja) |
| BR (1) | BR112020011625A2 (ja) |
| CA (1) | CA3085331A1 (ja) |
| MX (1) | MX2020006071A (ja) |
| TW (1) | TWI794361B (ja) |
| WO (1) | WO2019118360A1 (ja) |
Families Citing this family (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP7186460B2 (ja) * | 2017-08-07 | 2022-12-09 | エナンティア，エセ．エレ． | ２－［（１ｒ，６ｒ）－６－イソプロペニル－３－メチルシクロヘキサ－２－エン－１－イル］－５－ペンチルベンゼン－１，３－ジオールの共結晶 |
| US11667612B2 (en) * | 2017-10-25 | 2023-06-06 | Arizona Board Of Regents On Behalf Of The University Of Arizona | Compositions and methods for delivering pharmaceutical agents |
| US11993563B2 (en) * | 2018-10-31 | 2024-05-28 | Enantia S.L. | Solid compositions of cocrystals of cannabinoids |
| EP4025208A4 (en) * | 2019-09-06 | 2023-12-06 | Ebers Tech Inc. | CANNABIGEROL-PROLINE COCRYSTALS |
| US20230381134A1 (en) * | 2020-01-03 | 2023-11-30 | Purisys, Llc | Cocrystals of cannabinoids |
| US10981849B1 (en) * | 2020-02-20 | 2021-04-20 | Sci Pharmtech Inc. | Method for preparing cannabinoids |
| US20230183202A1 (en) * | 2020-05-19 | 2023-06-15 | Ebers Tech Inc. | Tetrahydrococannabinolic acid cocrystals |
| CN111882044B (zh) * | 2020-08-05 | 2021-09-14 | 四川大学 | 一种基于图神经网络的共晶预测方法、深度学习框架 |
| US11672761B2 (en) | 2020-11-16 | 2023-06-13 | Orcosa Inc. | Rapidly infusing platform and compositions for therapeutic treatment in humans |
| CN114177163B (zh) * | 2022-01-12 | 2023-05-02 | 刘树民 | 一种治疗高血压的药物 |
Family Cites Families (20)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4859674A (en) | 1987-06-12 | 1989-08-22 | Houston Biotechnology Incorporated | Pyrazine in prevention and treatment of strokes |
| US8034843B2 (en) | 2002-02-01 | 2011-10-11 | Gw Pharma Limited | Compositions comprising cannabinoids for treatment of nausea, vomiting, emesis, motion sickness or like conditions |
| GB2393182B (en) * | 2002-09-23 | 2007-03-14 | Gw Pharma Ltd | Method of preparing cannabidiol from plant material |
| WO2004064762A2 (en) * | 2003-01-21 | 2004-08-05 | S.S.C.I. Inc. | Novel cocrystallization |
| CA2513746C (en) * | 2003-02-28 | 2012-08-28 | Transform Pharmaceuticals, Inc. | Pharmaceutical co-crystal compositions of drugs such as carbamazeptine, celecoxib, olanzapine, itraconazole, topiramate, modafinil, 5-fluorouracil, hydrochlorothiazide, acetaminophen, aspirin, flurbiprofen, phenytoin and ibuprofen |
| US7091205B2 (en) | 2004-10-08 | 2006-08-15 | Yu Show Fu | Use of tetramethylpyrazine in the treatment of brain tumor |
| US8088773B2 (en) | 2005-05-12 | 2012-01-03 | The Texas A&M University System | Therapeutic compositions and methods |
| TWI370818B (en) * | 2006-04-05 | 2012-08-21 | Astellas Pharma Inc | Cocrystal of c-glycoside derivative and l-proline |
| WO2009094718A1 (en) * | 2008-01-31 | 2009-08-06 | Monash University | Methods of treating thromboembolic disorders |
| EP2123626A1 (en) * | 2008-05-21 | 2009-11-25 | Laboratorios del Dr. Esteve S.A. | Co-crystals of duloxetine and co-crystal formers for the treatment of pain |
| US20120202891A1 (en) * | 2009-04-29 | 2012-08-09 | University Of Kentucky Research Foundation | Cannabinoid-Containing Compositions and Methods for Their Use |
| US8576985B2 (en) | 2009-09-01 | 2013-11-05 | Aptuit (West Lafayette) Llc | Methods for indexing solid forms of compounds |
| US20110200531A1 (en) | 2009-09-14 | 2011-08-18 | The Regents Of The University Of California | Treatment and diagnosis of central nervous system disorders |
| US20120214753A1 (en) * | 2009-10-23 | 2012-08-23 | Keisuke Sakaura | Pharmaceutical composition for oral administration |
| WO2012116349A2 (en) * | 2011-02-26 | 2012-08-30 | Amplio Pharma, Llc | Novel cocrystals of ezetimibe |
| US20150224120A1 (en) * | 2011-09-14 | 2015-08-13 | Catherine Clelland | Compositions and methods for treating hyperprolinemia-associated mental disorders |
| US9822384B2 (en) | 2014-07-14 | 2017-11-21 | Librede Inc. | Production of cannabinoids in yeast |
| EP3253727A4 (en) | 2015-02-05 | 2018-08-08 | Colorado Can LLC | Purified cbd and cbda, and methods, compositions and products employing cbd or cbda |
| US10399920B2 (en) * | 2016-06-01 | 2019-09-03 | S&B Pharma, Inc. | Crystalline form of cannabidiol |
| JP7186460B2 (ja) * | 2017-08-07 | 2022-12-09 | エナンティア，エセ．エレ． | ２－［（１ｒ，６ｒ）－６－イソプロペニル－３－メチルシクロヘキサ－２－エン－１－イル］－５－ペンチルベンゼン－１，３－ジオールの共結晶 |
-
2018
- 2018-12-10 MX MX2020006071A patent/MX2020006071A/es unknown
- 2018-12-10 US US16/214,913 patent/US20190177258A1/en not_active Abandoned
- 2018-12-10 JP JP2020550056A patent/JP7429013B2/ja active Active
- 2018-12-10 KR KR1020207018827A patent/KR20200097285A/ko not_active Application Discontinuation
- 2018-12-10 CN CN201880079622.4A patent/CN111447929B/zh active Active
- 2018-12-10 EP EP18887462.2A patent/EP3723752B1/en active Active
- 2018-12-10 AU AU2018383598A patent/AU2018383598B2/en active Active
- 2018-12-10 BR BR112020011625-4A patent/BR112020011625A2/pt unknown
- 2018-12-10 CA CA3085331A patent/CA3085331A1/en active Pending
- 2018-12-10 TW TW107144375A patent/TWI794361B/zh active
- 2018-12-10 WO PCT/US2018/064773 patent/WO2019118360A1/en active Application Filing
-
2019
- 2019-04-26 US US16/396,414 patent/US10604467B2/en active Active
-
2020
- 2020-03-31 US US16/835,383 patent/US11364202B2/en active Active
-
2022
- 2022-06-20 US US17/844,544 patent/US20230404939A1/en active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| JP2021505674A (ja) | 2021-02-18 |
| WO2019118360A1 (en) | 2019-06-20 |
| AU2018383598A1 (en) | 2020-06-18 |
| US20210299048A1 (en) | 2021-09-30 |
| TW201927733A (zh) | 2019-07-16 |
| CN111447929B (zh) | 2024-05-31 |
| US20190177258A1 (en) | 2019-06-13 |
| EP3723752A4 (en) | 2021-10-20 |
| AU2018383598B2 (en) | 2024-03-07 |
| US10604467B2 (en) | 2020-03-31 |
| EP3723752B1 (en) | 2024-08-21 |
| BR112020011625A2 (pt) | 2020-11-17 |
| US20230404939A1 (en) | 2023-12-21 |
| TWI794361B (zh) | 2023-03-01 |
| KR20200097285A (ko) | 2020-08-18 |
| US20190300466A1 (en) | 2019-10-03 |
| US11364202B2 (en) | 2022-06-21 |
| CN111447929A (zh) | 2020-07-24 |
| EP3723752A1 (en) | 2020-10-21 |
| CA3085331A1 (en) | 2019-06-20 |
| JP7429013B2 (ja) | 2024-02-07 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MX2020006071A (es) | Nuevas formas solidas de cannabidiol y sus usos. | |
| MY186296A (en) | Novel promoter and use thereof | |
| MX2020006812A (es) | Degradadores de cinasas asociadas al receptor de interleucina-1 (irak) y usos de los mismos. | |
| MY201925A (en) | Macrocyclic compounds and uses thereof | |
| MX2018002999A (es) | Composiciones de inoculante estables y metodos para producir las mismas. | |
| MX2019002453A (es) | Compuestos de tetraciclina y metodos de uso de los mismos. | |
| WO2017176957A8 (en) | Mdm2 protein degraders | |
| SA519402288B1 (ar) | مركب بيريميدين واستخداماته الصيدلانية | |
| MX2020001832A (es) | Activadores de piruvato quinasas para usar en el tratamiento de trastornos en la sangre. | |
| TN2019000211A1 (en) | Antitumoral compounds | |
| MX2020001793A (es) | Inhibidores del receptor de hidrocarburos de arilo (ahr) y usos de los mismos. | |
| SA519410259B1 (ar) | مركب كبير الحلقات واستخداماته | |
| ZA202309446B (en) | Rapamycin analogs and uses thereof | |
| MX2020006596A (es) | Hidroxiisoxazolinas y derivados de estos. | |
| MX2019010950A (es) | Composicion de fotosensibilizador que contiene fenalen-1-ona, compuesto de fenalen-1-ona, asi como su uso. | |
| MX2018005785A (es) | Conjugados de anticuerpo anti-cd22-maytansina y metodos de uso de los mismos. | |
| MX2016008638A (es) | Macrociclos odorizantes sutiles y amaderados. | |
| MX2021006011A (es) | Un inhibidor de la quinasa aurora a para su uso en el tratamiento del neuroblastoma. | |
| SA520411726B1 (ar) | مشتق فينيل بيريدين جديد وتركيبة صيدلانية تشتمل عليه | |
| MX2019013250A (es) | 2,3,7-trimetiloct-6-enil acetato y 3,7-dimetil-2-metilen-oct-6-eni l acetato y derivados de estos y su uso como sustancias quimicas aromaticas. | |
| PH12020550649A1 (en) | Anti-hbv tetrahydroisoxazolo[4,3-c]pyridine compounds | |
| MX2019004312A (es) | Odorante de lirio del valle. | |
| GEP20186893B (en) | Pyrazines modulators of gpr6 | |
| MX2020005707A (es) | Profarmacos de creatina, composiciones y metodos de uso de estos. | |
| MX2020012718A (es) | Derivados de benzodiazepinas novedosos y usos de los mismos. |